Super Micro cuts 2025 guidance amid customer order delays and economic uncertainty, sending shares lower despite CEO's optimism about AI server technology leadership.
Novo Nordisk cuts forecasts amid U.S. drug rivalry, with compounded versions and Eli Lilly's competition limiting its weight-loss drug Wegovy's market penetration.
Super Micro cuts 2025 guidance amid customer order delays and economic uncertainty, sending shares lower despite CEO's optimism about AI server technology leadership.
Novo Nordisk cuts forecasts amid U.S. drug rivalry, with compounded versions and Eli Lilly's competition limiting its weight-loss drug Wegovy's market penetration.